WO2004081021A3 - Oligonucleotide mimetics - Google Patents

Oligonucleotide mimetics Download PDF

Info

Publication number
WO2004081021A3
WO2004081021A3 PCT/US2004/007405 US2004007405W WO2004081021A3 WO 2004081021 A3 WO2004081021 A3 WO 2004081021A3 US 2004007405 W US2004007405 W US 2004007405W WO 2004081021 A3 WO2004081021 A3 WO 2004081021A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide mimetics
aptamers
mimetics
oligonucleotide
ctlr
Prior art date
Application number
PCT/US2004/007405
Other languages
French (fr)
Other versions
WO2004081021A2 (en
Inventor
Eli Gilboa
Sandra Santulli-Marotto
Bruce A Sullenger
Christopher P Rusconi
Original Assignee
Univ Duke
Eli Gilboa
Sandra Santulli-Marotto
Bruce A Sullenger
Christopher P Rusconi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Eli Gilboa, Sandra Santulli-Marotto, Bruce A Sullenger, Christopher P Rusconi filed Critical Univ Duke
Priority to US10/548,532 priority Critical patent/US20060246123A1/en
Priority to AU2004220036A priority patent/AU2004220036A1/en
Priority to CA002518782A priority patent/CA2518782A1/en
Priority to EP04720328A priority patent/EP1601681A4/en
Priority to JP2006507070A priority patent/JP2006522101A/en
Publication of WO2004081021A2 publication Critical patent/WO2004081021A2/en
Publication of WO2004081021A3 publication Critical patent/WO2004081021A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

The present invention relates, in general, to a method of using aptamers to modulate the immune system and, in particular, to a method of inhibiting CTLR-4 function and to aptamers suitable for use in such a method.
PCT/US2004/007405 2003-03-12 2004-03-12 Oligonucleotide mimetics WO2004081021A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/548,532 US20060246123A1 (en) 2003-03-12 2004-03-12 Oligonucleotide mimetics
AU2004220036A AU2004220036A1 (en) 2003-03-12 2004-03-12 Oligonucleotide mimetics
CA002518782A CA2518782A1 (en) 2003-03-12 2004-03-12 Oligonucleotide mimetics
EP04720328A EP1601681A4 (en) 2003-03-12 2004-03-12 Oligonucleotide mimetics
JP2006507070A JP2006522101A (en) 2003-03-12 2004-03-12 Oligonucleotide analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45383103P 2003-03-12 2003-03-12
US60/453,831 2003-03-12

Publications (2)

Publication Number Publication Date
WO2004081021A2 WO2004081021A2 (en) 2004-09-23
WO2004081021A3 true WO2004081021A3 (en) 2005-06-09

Family

ID=32990828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007405 WO2004081021A2 (en) 2003-03-12 2004-03-12 Oligonucleotide mimetics

Country Status (6)

Country Link
US (1) US20060246123A1 (en)
EP (1) EP1601681A4 (en)
JP (1) JP2006522101A (en)
AU (1) AU2004220036A1 (en)
CA (1) CA2518782A1 (en)
WO (1) WO2004081021A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048685A2 (en) * 2006-10-19 2008-04-24 Duke University Ox40 aptamers
CA2622629A1 (en) * 2005-09-15 2007-03-29 Duke University Aptamers as agonists
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
AU2006311586A1 (en) * 2005-11-08 2007-05-18 Avi Biopharma, Inc. Immunosuppression compound and treatment method
US20080026947A1 (en) * 2006-02-08 2008-01-31 Gmeiner William H Cytotoxic nucleotides for targeted therapeutics
WO2009045545A2 (en) * 2007-10-04 2009-04-09 Duke University Antidotes for agonistic aptamers
JP5210620B2 (en) * 2007-12-19 2013-06-12 独立行政法人科学技術振興機構 Method and use of peptide aptamer library
WO2010019446A1 (en) 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
US9284559B2 (en) 2009-04-14 2016-03-15 Wake Forest University Health Sciences Multivalent aptamer complexes
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
US20130224237A1 (en) * 2010-07-20 2013-08-29 University Of Miami Inhibition of nonsense mediated decay pathways
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
EP2734232B1 (en) * 2011-07-19 2017-11-01 Philogen S.p.A. Sequential anti-ctla4 and targeted il-2 therapy
US9486533B2 (en) 2013-09-27 2016-11-08 Wake Forest University Health Sciences Pharmaceutical compositions for high-capacity targeted delivery
US10711272B2 (en) 2014-01-21 2020-07-14 City Of Hope CTLA-4 aptamer siRNA species
WO2016019255A1 (en) * 2014-07-31 2016-02-04 Academia Sinica Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity
ES2908056T3 (en) 2014-10-10 2022-04-27 Idera Pharmaceuticals Inc Cancer treatment by TLR9 agonists with checkpoint inhibitors
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
CN109983121A (en) 2016-06-30 2019-07-05 昂克诺斯公司 The pseudotyping oncolytic virus of therapeutical peptide delivers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
US11634772B2 (en) 2017-03-23 2023-04-25 Duke University Antidote-mediated reversal of extracellular aptamer staining
US11713464B2 (en) 2017-09-08 2023-08-01 Duke University Nucleolin-targeting aptamers and methods of using the same
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (en) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 Pyrrolobenzodiazepine antibody conjugates
JP2021508477A (en) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド Oncolytic virus delivery of therapeutic polypeptides
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
BR112021020411A2 (en) * 2019-04-11 2022-03-15 Univ Arkansas cd40-specific DNA aptamers as vaccine adjuvants
IL297442A (en) 2020-04-22 2022-12-01 Iovance Biotherapeutics Inc Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
DK0989858T3 (en) * 1997-06-12 2004-08-09 Applied Research Systems CD28 / CTLA-4 inhibitory peptidomimetics and pharmaceutical compositions thereof
AU3909199A (en) * 1997-12-15 1999-07-05 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
EP1137436B1 (en) * 1998-12-03 2008-06-04 The Regents Of The University Of California Stimulation of T-cells against self antigens using CTLA-4 blocking agents
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
ATE482227T1 (en) * 2001-05-25 2010-10-15 Univ Duke MODULATORS OF PHARMACOLOGICAL AGENTS
WO2004058801A2 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CERCHIA L.: "Nucleic acid aptamers in cancer medicine", FEBS, vol. 528, 28 August 2002 (2002-08-28), pages 12 - 16, XP004383225 *
CORDEIRO M.F.: "Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome", GENE THERAPY, vol. 10, 2003, pages 59 - 71, XP002985586 *
EATON B.E.: "Post SELEX combinatorial optimization of aptamers", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 5, 1997, pages 1087 - 1096, XP002985590 *
LINSLEY P.S.: "Coexpression and functional cooperation of CTLA-4 and CD28 onactivated T lymphocytes", J. EXP. MED., vol. 176, December 1992 (1992-12-01), pages 1595 - 1604, XP002985589 *
NOCENTINI G.: "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis", PNAS, vol. 94, June 1997 (1997-06-01), pages 6216 - 6221, XP002912041 *
PLUVINET R.: "RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells", BLOOD, vol. 104, 1 December 2004 (2004-12-01), pages 3642 - 3646, XP002985587 *
TAM R.C.: "Oligonucleotide-mediated inhibition of CD28 expression induces human T cell hyperresponsiveness and manifest impaired contact hypersensitivity in mice", J. OF IMMUNOLOGY, vol. 158, 1999, pages 200 - 208, XP000941709 *
WEINBERG A.D.: "Blocking OX-40/OX-40 ligand in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephaomyelitis", J OF IMMUNOLOGY, vol. 162, 1999, pages 1818 - 1826, XP002985588 *
WHITE R.: "Generation of species cross-reactive aptamers using 'toggle' selex", MOLECULAR THERAPY, vol. 4, December 2001 (2001-12-01), pages 567 - 573, XP002985591 *

Also Published As

Publication number Publication date
WO2004081021A2 (en) 2004-09-23
AU2004220036A1 (en) 2004-09-23
EP1601681A4 (en) 2006-11-29
CA2518782A1 (en) 2004-09-23
US20060246123A1 (en) 2006-11-02
EP1601681A2 (en) 2005-12-07
JP2006522101A (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2004081021A3 (en) Oligonucleotide mimetics
ZA200301077B (en) Linked progressive jackpot system.
AU2003230668A8 (en) Capped bill systems, methods and products
GB2407684C (en) Transaction method and system
EG23415A (en) Self-refrigerated lng process.
GB0318570D0 (en) Banking systems
AU2003278693A1 (en) Identity verification system
ZA200407396B (en) Communication system and method.
AU2003901043A0 (en) Transaction system
GB2397341B (en) Fuel pressure damping system and method
WO2005119255A3 (en) Constrained cis-diol-borate bioconjugation system
AU2003277453A1 (en) Oil treatment system
EP1665075A4 (en) Package metadata and targeting/synchronization service providing system using the same
GB2399209B (en) Secure transaction system
ZA200309960B (en) Gaming system.
AU2003211471A1 (en) Calculation device and method and point or coupon service system
GB0308199D0 (en) Combined microbiology system
WO2006023947A3 (en) A system and method for heightening a humoral immune response
ZA200101940B (en) System and method for internet anonymous id transactions.
ZA200301736B (en) Surface treatment system.
ZA200408351B (en) System verification.
WO2006031377A3 (en) A system and method related to enhancing an immune system
AP2006003500A0 (en) Transaction verification system.
ZA200405150B (en) Security systems.
ZA200503006B (en) Vending terminal, system and method.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004720328

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006507070

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004220036

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2518782

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004220036

Country of ref document: AU

Date of ref document: 20040312

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220036

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004720328

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006246123

Country of ref document: US

Ref document number: 10548532

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10548532

Country of ref document: US